Company news

Spero Therapeutics, Inc. news in 2020

Spero Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer

December 16, 2020

Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease

December 9, 2020

Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer

December 1, 2020

Spero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update

November 4, 2020

Spero Therapeutics Announces Pricing of Securities Offering

September 10, 2020

Spero Therapeutics Announces Proposed Public Offering

September 8, 2020

Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis

September 7, 2020

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720

August 30, 2020

Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update

August 5, 2020

Spero Therapeutics to Provide Business Update and Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020

July 28, 2020

Spero Therapeutics Announces First Quarter 2020 Operating Results and Provides Business Update

May 7, 2020

Spero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection

May 4, 2020

Spero Therapeutics to Provide Business Update and Report First Quarter 2020 Financial Results on Friday, May 8, 2020

May 3, 2020

Spero Announces Appointment of Scott Jackson to its Board of Directors

April 15, 2020

Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update

March 15, 2020

Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection

March 10, 2020

Spero Therapeutics Announces Closing of Rights Offering

March 4, 2020

Spero Therapeutics Announces Commencement of Rights Offering

February 10, 2020

Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development

February 4, 2020

Spero Therapeutics Announces Proposed Rights Offering

January 29, 2020

Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense

January 12, 2020

Calls in 2020

Decks in 2020